InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · Real-Time Price · USD
0.6753
+0.0252 (3.88%)
May 15, 2026, 2:52 PM EDT - Market open
InMed Pharmaceuticals Revenue
InMed Pharmaceuticals had revenue of $4.94M in the twelve months ending March 31, 2026, up 285.22% year-over-year. In the fiscal year ending June 30, 2025, InMed Pharmaceuticals had annual revenue of $4.94M with 7.50% growth.
Revenue (ttm)
$4.94M
Revenue Growth
+285.22%
P/S Ratio
0.59
Revenue / Employee
$380,203
Employees
13
Market Cap
3.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.94M | 344.90K | 7.50% |
| Jun 30, 2024 | 4.60M | 462.17K | 11.18% |
| Jun 30, 2023 | 4.14M | 3.05M | 279.61% |
| Jun 30, 2022 | 1.09M | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 41.71M |
| IM Cannabis | 39.92M |
| Sunshine Biopharma | 36.31M |
| cbdMD | 19.09M |
| Universe Pharmaceuticals INC | 17.86M |
| Sonoma Pharmaceuticals | 17.72M |
| China SXT Pharmaceuticals | 1.54M |
| RedHill Biopharma | 286.00K |
INM News
- 8 days ago - InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - Newsfile Corp
- 17 days ago - InMed Pharmaceuticals Amends Preferred Investment Options - Newsfile Corp
- 6 weeks ago - InMed receives Nasdaq notification regarding minimum bid price compliance - TheFly
- 6 weeks ago - InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Newsfile Corp
- 7 weeks ago - InMed Pharmaceuticals announces preclinical data on effects of INM-901 - TheFly
- 7 weeks ago - InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Newsfile Corp
- 7 weeks ago - InMed Pharmaceuticals files $50M mixed securities shelf - TheFly
- 2 months ago - InMed Pharmaceuticals Transcript: Sidoti March Small-Cap Virtual Conference - Transcripts